Fanconi Anemisi Tip C Tedavisi için Gen Terapisi

Sade dilde özet

Bu çalışma, Fanconi Anemisi (Fanconi's Anemia) tip C hastalığının tedavisinde bir gen terapisi yaklaşımını (genetik olarak değiştirilmiş CD34+ hücreler) inceliyor. Katılımcılar, FACC gen mutasyonu doğrulanmış hastalardır. Faz 1 aşamasında yürütülmüş ve tamamlanmıştır.

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

Faz 1 (Phase 1)

Durum

Tamamlandı

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Müdahale

Transduced CD34+ Cells

Başlangıç

03.12.1993

Tahmini bitiş

11.02.2009

Ülkeler

United States

İlgili genler

Merkezler

• Bethesda, United States

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

* INCLUSION CRITERIA:

Patients must meet the following criteria within 30 days prior to study entry (Day 0) unless otherwise noted.

Males or females, age greater than or equal to 5 years of age.

Diagnosis of Fanconi anemia, complementation group C, as confirmed by 1) Diepoxybutane or mitomycin C testing and 2) DNA analysis indicating FACC mutations.

Adequate baseline organ function as assessed by the following laboratory values within 30 days prior to study entry (day -30 to 0).

Adequate renal function with estimated creatinine clearance greater than 50 ml/min. (This will be determined by serum creatinine and 24-hour urine creatinine ordered concurrently).

Adequate liver function with SGOT, SGPT and alkaline phosphatase less than or equal to 5 times the ULN (if transaminases greater than the upper limit of normal (ULN), patients should have a hepatitis B surface antigen (HBsAG) test prior to study entry. Patients may not enter the study if HBsAG is positive).

PT and PTT not more than 1.5 times the ULN.

Serum Amylase less than or equal to 1.5 times the ULN.

Bilirubin less than or equal to 3.0 mg/dL.

Triglyceride less than 400 mg/dl.

Ability to give informed consent.

Normal cardiac function by history and exam.

Resting transcutaneous oxygen saturation greater than 90 percent on room air.

Karnofsky Performance Status greater than or equal to 40.

Although there are no blood count criteria for inclusion in this study, preference will be given to patients with significant marrow failure as reflected by anemia, neutropenia, and/or thrombocytopenia. Furthermore, we intend to first enroll adults and older children, to the extent possible, before enrolling younger children.

EXCLUSION CRITERIA:

Patients who meet any one of the following criteria will be excluded from study entry:

Patients presenting with acute leukemia or bone marrow aspirate revealing greater than 10 percent blasts.

Pregnant or lactating females (all patients must practice adequate birth control and females of child-bearing potential must have a negative serum beta-HCG pregnancy test (within Day -7 to Day 0).

Acute infection: any acute viral, bacterial, or fungal infection which requires specific therapy. Acute therapy must have been completed within 14 days prior to study treatment.

Hepatitis-B surface antigen positive patients.

HIV-infected patients.

Acute medical problems such as ischemic heart or lung disease that may be considered an unacceptable anesthetic or operative risk.

No patients with any underlying conditions which would contraindicate therapy with study treatment (or allergies to reagents used in this study).

Patients less than 25 kg in weight .

Patients who elect bone marrow transplantation.